VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
Alaska Native and American Indian (AN/AI) people have unique pharmacogene variation that may affect warfarin disposition and therapeutic response. We performed targeted genotyping for cytochrome P450 (CYP)2C9, vitamin K epoxide oxidase reductase complex subunit 1 (VKORC1), CYP4F2, CYP4F11, and gamma...
Main Authors: | Lindsay M. Henderson, Renee F. Robinson, Lily Ray, Burhan A. Khan, Tianran Li, Denise A. Dillard, Brian D. Schilling, Mike Mosley, Patricia L. Janssen, Alison E. Fohner, Allan E. Rettie, Kenneth E. Thummel, Timothy A. Thornton, David L. Veenstra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12611 |
Similar Items
-
Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes
by: Mark Johnson, et al.
Published: (2014-01-01) -
Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
by: Jia LQ, et al.
Published: (2017-03-01) -
Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
by: Alison E. Fohner, et al.
Published: (2021-07-01) -
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
by: Andrea L Jorgensen, et al.
Published: (2012-01-01) -
Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
by: Behzad Poopak, et al.
Published: (2016-02-01)